Amylin Analog Therapeutics Market
完整報告名稱與涵蓋範圍
Amylin Analog Therapeutics Market Size, Share & Trends Analysis Report, By Product Type (Amylin Analog Monotherapies, Amylin and GLP-1 Fixed-Dose Combinations, Dual Amylin and Calcitonin Receptor Agonists), By Indication (Obesity and Weight Management, Type 2 Diabetes, Type 1 Diabetes Adjunctive Therapy), By Dosing Regimen (Daily Injection, Weekly Injection, Oral and Other Formulations), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
The amylin analog therapeutics market covers medicines that activate amylin receptors, including long-acting amylin analogs, dual amylin and calcitonin receptor agonists and fixed-dose combinations with GLP-1 receptor agonists, for obesity, type 2 diabetes and adjunctive use in type 1 diabetes. The single marketed short-acting amylin analog provides the commercial baseline; most revenue in the forecast is contingent on late-stage combination and monotherapy programs reaching approval, which the study models explicitly.
Interest in the mechanism has surged because amylin agonism produces weight loss with a different tolerability profile and potential lean-mass preservation compared with incretin therapies, and because combining amylin and GLP-1 agonism has delivered weight reductions approaching bariatric surgery in late-stage trials. Sponsors are advancing weekly monotherapies positioned for patients who cannot tolerate GLP-1 agents, dual receptor agonists with once-monthly ambitions and combination regimens intended as next-generation franchise anchors. Manufacturing of peptide combinations, device design for co-formulated products and evidence on durability after treatment cessation will influence commercial performance.
North America and Europe will dominate initial uptake, while licensing of Chinese-origin amylin assets and expanding obesity treatment in Asia broaden the competitive base. The field is led by incretin incumbents, with several biotechnology companies contributing differentiated amylin candidates.
The InsightAce study delivers revenue forecasts in US$ across all product type, indication, dosing regimen and distribution channel and regional segments for 2026-2035, alongside segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Amylin Analog Therapeutics Market Snapshot
Chapter 4. Global Amylin Analog Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Product Type Estimates & Trend Analysis
5.1. Product Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Product Type:
5.2.1. Amylin Analog Monotherapies
5.2.2. Amylin and GLP-1 Fixed-Dose Combinations
5.2.3. Dual Amylin and Calcitonin Receptor Agonists
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Obesity and Weight Management
6.2.2. Type 2 Diabetes
6.2.3. Type 1 Diabetes Adjunctive Therapy
Chapter 7. Market Segmentation 3: By Dosing Regimen Estimates & Trend Analysis
7.1. Dosing Regimen & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Dosing Regimen:
7.2.1. Daily Injection
7.2.2. Weekly Injection
7.2.3. Oral and Other Formulations
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
8.2.1. Retail Pharmacies
8.2.2. Specialty and Online Pharmacies
8.2.3. Hospital Pharmacies
Chapter 9. Amylin Analog Therapeutics Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Novo Nordisk A/S
11.2. Zealand Pharma A/S
11.3. AstraZeneca plc
11.4. Eli Lilly and Company
11.5. Amgen Inc.
11.6. Roche Holding AG (Carmot Therapeutics)
11.7. Pfizer Inc. (Metsera)
11.8. Structure Therapeutics Inc.
11.9. Gubra A/S
11.10. Viking Therapeutics, Inc.
11.11. AbbVie Inc.
11.12. Innovent Biologics, Inc.
11.13. Hengrui Pharmaceuticals Co., Ltd.
11.14. Regeneron Pharmaceuticals, Inc.
11.15. Ascendis Pharma A/S
圖表清單 List of Tables & Figures
Table 1. Global Amylin Analog Therapeutics Market Revenue Forecast by Product Type, 2026-2035 (US$ Mn)
Figure 1. Global Amylin Analog Therapeutics Market Segmentation Overview
Table 2. Global Amylin Analog Therapeutics Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Amylin Analog Therapeutics Market Share by Product Type, 2026 & 2035
Table 3. Global Amylin Analog Therapeutics Market Revenue Forecast by Dosing Regimen, 2026-2035 (US$ Mn)
Figure 3. Amylin Analog and Combination Pipeline by Phase and Expected Launch Window
Table 4. Global Amylin Analog Therapeutics Market Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 4. Global Amylin Analog Therapeutics Market Share by Indication, 2026 & 2035
Table 5. North America Amylin Analog Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Weight-Loss and Tolerability Positioning of Amylin Mechanisms Versus Incretins
Table 6. Europe Amylin Analog Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Amylin Analog Therapeutics Growth Opportunity Analysis
Table 7. Asia Pacific Amylin Analog Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Partnering and Licensing Activity for Amylin Assets, 2023-2026
Table 8. Latin America Amylin Analog Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Amylin Analog Therapeutics Market Participants
Table 9. Middle East & Africa Amylin Analog Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們